One of the highest priorities of HIV research is to have access to long-acting pharmaceutical formulations for HIV treatment and prevention. Our research aims at fabrication of combination antiretroviral (cARV) drugs loaded nano-system for PReP. Presently we report on the pharmacokinetics of tenofovir disoproxil fumurate (TDF) and elvitegravir (EVG) loaded nanoparticles (TDF+EVG NP) in humanized mice (huNSG).
Formulation of cARV loaded nanoparticles (NP) by oil-in-water emulsion. Poly(lactic-co-glycolic acid) (PLGA), a biocompatible polymer was used to formulate TDF+EVG drugs loaded NPs (TDF+EVG NPs) using standard methods. For pharmacokinetic studies, female humanized NSG mice (Jackson Labs, Inc.) were treated with TDF+EVG NPs (50 mg/kg administered SubQ in 1 ml D5W). At specific time points (1, 2, 4, 7, 10, and 14 days post-SubQ administration), mice (n=3/time point) were euthanized, blood harvested, centrifuged, and plasma was analyzed for tenofovir (TNF) and EVG drug levels. The plasma concentrations of the drugs were measured by high-performance liquid chromatography (HPLC). Intra-day and inter-day variability was < 10%. Plasma concentration-vs-time was modeled using non-compartmental modeling. Peak plasma levels and time to peak were determined by graph inspection.
TDF+EVG NP size averaged 136.7 nm and drug entrapment efficiency was 41.7% and 39.7%, respectively. Mean (+ SD) peak plasma TNF and EVG levels were 1.2 + 0.28 and 0.2 + 0.25 mcg/mL and time to peak was 6.3 and 4.3 days after SubQ administration. Using non-compartmental modeling, plasma PK parameters for TNF and EVG from NP formulation (TDF/EVG NP), respectively, were AUC0-tau (TNF) 13.5 + 3.1 and EVG 2.2 + 2.9 mg x h/L. Elimination half-life for TNF and EVG averaged 14.9 + 15.1 and 15.2 + 14.9 days, respectively from the NP formulation. Apparent volume of distribution (Vd) averaged 0.027 and 0.497 L/kg and total body clearance (Cl) averaged 0.002 and 0.052 L/day/kg for TNF and EVG, respectively. Based on modeling, a dosing interval of one SubQ dose every 28 days would provide detectable drug in plasma throughout the dosing interval above 50 mcg/mL.
The simultaneous administration of TAF and EVG in single NP formulation shows prolonged PK parameters of TNF and EVG. Further tissue concentrations in colon and female reproductive tract are needed to determine if this will be an appropriate prevention option. This is the first report of using NRTI+ISTI in NP formulation for PReP.